Picard Medical FY2025 revenue $4.94M (+12.5% YoY); U.S. rev +33.5%

Picard Medical, Inc.

Revenue $4.94M (+12.5% YoY); U.S. revenue +33.5% to 88.25% of total.
Net loss ~$27M (incl. $14.5M non-cash); cash burn $15.67M; IPO raised $35.55M.
Emperor TAH in preclinical; FDA Breakthrough designation possible in 2026; 2028 clinical study target.
Manufacturing: valve assembly in-house, driver transfer to China, second source qualification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.